Table 1. In vitro uptake inhibitory potency (pIC50) and apparent binding affinity (pKi) of fluoxetine, duloxetine, atomoxetine and esreboxetine in rat cortical membrane or synaptosomal preparations, respectively (n = 3–12).
| Compound | pIC50 | pKi | |||
| RatSERT | RatNET | Transporterselectivity | RatSERT | RatNET | |
| Fluoxetine | 7.8±0.1 | 6.1±0.1 | 50-fold SERT | 8.8±0.1 | 6.3±0.3 |
| Duloxetine | 9.1±0.1 | 8.4±0.2 | 5-fold SERT | 10.0±0.1 | 8.4±0.1 |
| Atomoxetine | 7.1±0.1 | 8.6±0.2 | 30-fold NET | 7.8±0.1 | 8.7±0.2 |
| Esreboxetine | 5.3±0.1 | 9.6±0.2 | 20,000-fold NET | 5.6± <0.1 | 9.2±0.1 |